PET Response Criteria for Solid Tumors Predict Survival at Three Months After Intra-Arterial Resin-Based 90Yttrium Radioembolization Therapy for Unresectable Intrahepatic Cholangiocarcinoma
PET Response Criteria for Solid Tumors Predict Survival at Three Months After Intra-Arterial Resin-Based 90Yttrium Radioembolization Therapy for Unresectable Intrahepatic Cholangiocarcinoma
复制标题
DOI：
10.1097/rlu.0000000000000557
复制
发表时间：
2014-11-01
影响因子：
10.6
通讯作者：
Kim, Hyun S.
中科院分区：
文献类型：
--
作者：
Camacho, Juan C.;Kokabi, Nima;Kim, Hyun S.
Purpose: PET Response Criteria for Solid Tumors (PERCIST) were assessed and correlated with survival analysis after resin-based (90)Yttrium (Y-90) radioembolization therapy for intrahepatic cholangiocarcinoma (ICC).Patients and Methods: Target and overall PERCIST and Response Criteria for Solid Tumors (RECIST) treatment responses were assessed in consecutive patients treated with Y-90 radioembolization for ICC refractory to standard chemotherapy. Significant measurable tumor was defined as 1 cm or greater in diameter and SUVpeak of 2.5 or greater in targeted and nontargeted lesions. The PERCIST defines complete response as resolution of F-18-FDG uptake within measurable lesions, and partial response as 30% reduction in F-18-FDG peak standardized uptake value in measurable lesions. Objective response included partial response and complete response. Survival analysis by Kaplan-Meier and log-rank proportional models was performed using SPSS software version 20.0 (IBM, Armonk, NY), and significance was set at P < 0.05.Results: Median overall survival (OS) of 9 consecutive patients (56% women; mean age, 58 years) from Y-90 therapy was 21.7 months. At 3 months, PERCIST objective response rate of target lesions was 77.7 %, and target objective response on PERCIST correlated significantly to prolonged OS (P = 0.022). Overall objective PERCIST response at 3 months had significant correlation with OS (P = 0.011). Probability of death was significantly higher in overall nonresponders by PERCIST (hazard ratio, 12.3). No objective response was seen with RECIST.Conclusions: In patients with unresectable ICC refractory to standard chemotherapy, PERCIST at 3 months for assessment of imaging response after Y-90 radioembolization therapy predict OS.
